MedTrace Logo

A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC

NCT03904823 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2022-07-07

No results posted yet for this study

Summary

The study is being conducted to evaluate the efficacy, safety and tolerability of famitinib combined with HS-10296 in subjects with advanced EGFR-mutant NSCLC.

Conditions

  • EGFR-mutant Non-Small Cell Lung Cancer

Interventions

DRUG

famitinib po

Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.

DRUG

HS-10296 po

Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Caicun Zhou, PhD · Shanghai Pulmonary Hospital, Shanghai, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-25
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03904823 on ClinicalTrials.gov